SciCombinator

Discover the most talked about and latest scientific content & concepts.

Abstract
Trastuzumab improves survival in HER2+ breast cancer patients, with some evidence of adverse cardiac side effects. Current recommendations are to give adjuvant trastuzumab for one year or until recurrence, although trastuzumab treatment for only 9 or 10 weeks has shown similar survival rates to 12-month treatment. We present here a multi-arm joint analysis examining the relative cost-effectiveness of different durations of adjuvant trastuzumab.
Tweets*
5
Facebook likes*
0
Reddit*
0
News coverage*
12
Blogs*
0
SC clicks
0
Concepts
HER2/neu, Health economics, Metastasis, Pharmacoeconomics, Trastuzumab, Cancer, Chemotherapy, Breast cancer
MeSH headings
-
comments powered by Disqus

* Data courtesy of Altmetric.com